Pregnant women may benefit from RSV vaccine

Results of a study shared at the eight Vaccine & ISV Congress in Philadelphia on Sunday showed that pregnant women may benefit from the Novavax, Inc., respiratory syncytial virus (RSV) F-Protein Nanoparticle vaccine.

In clinical studies, 330 women of childbearing age were given either the vaccine for RSV or a placebo. While 20 percent of the placebo recipients showed signs of RSV, just 10 percent of the vaccine recipients showed signs of the infection. These findings demonstrate a 50 percent decrease in infectio...